Eli Lilly, Nvidia Revolutionise Drug Discovery

Get ready for a pharmaceutical revolution!

Eli Lilly and Nvidia are joining forces to construct the pharmaceutical industry's mightiest supercomputer and AI factory, aiming to turbocharge drug discovery and development. This dynamic duo is set to redefine how quickly and efficiently new medicines reach patients.

Picture this: a supercomputer powered by over 1,000 of Nvidia's Blackwell Ultra GPUs, acting as a colossal microscope for biologists. This cutting-edge tool will allow scientists to train AI models on millions of experiments, significantly broadening the horizons of drug discovery. Eli Lilly's Chief AI Officer, Thomas Fuchs, likens it to a novel scientific instrument, enabling feats previously unimaginable.

---

Want to hear more? Join Mal & Matt on the Property AI Report Podcast each week!

Access from your preferred podcast provider by clicking here

---

While the AI factory won't yield immediate returns, it promises to be a game-changer by the decade's end. The industry is still in its early AI adoption stages, but the number of AI-discovered drugs entering clinical trials is on the rise. Eli Lilly's TuneLab platform, launched in September, allows biotech companies to access these AI models, providing a head start in drug discovery.

Through federated learning, companies can benefit from Lilly's AI models without directly sharing data, fostering collaboration and innovation. The supercomputer will also aid in precision medicine, tailoring treatments based on individual genetic, environmental, and lifestyle differences.

With Eli Lilly and Nvidia at the helm, the future of drug discovery is brighter than ever. The promise of precision medicine is within reach, and this partnership is paving the way for a healthier tomorrow.

---

Want to hear more? Join Mal & Matt on the Property AI Report Podcast each week!

Access from your preferred podcast provider by clicking here

---

Made with TRUST_AI - see the Charter: https://www.modelprop.co.uk/trust-ai